Eradivir’s EV25 Shows Strong Safety and Efficacy in Phase IIa Influenza Trial

Eradivir has completed its Phase IIa clinical trial of EV25, demonstrating that the therapy is well-tolerated, safe, and effective in reducing influenza symptoms and viral loads. The first-in-human, double-blind, randomized, placebo-controlled, single ascending dose study assessed efficacy, pharmacokinetics, pharmacodynamics, and safety.

The trial was conducted in two parts: part one included healthy adults, while part two enrolled participants inoculated with attenuated H3N2 influenza virus. A single 300 mg dose of EV25 significantly reduced the severity and duration of total influenza symptoms, as measured by FLU-PRO total scores, and lowered peak symptom scores.

EV25 also reduced the incidence of lower respiratory tract infections (35.7% vs 85.7% for placebo) and achieved a 98% reduction in median viral load AUC. Effects were observed early in infection, indicating rapid antiviral activity.

The therapy showed no dose-dependent safety trends. Phase IIb studies are planned in Europe and the US during the 2026–27 influenza season.

20-10-2025